institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published Washington, United StatesUpdated

Prevail DCB gains expanded CE mark indications - Cardiovascular News

Summary by Cardiovascular News
Medtronic has received CE mark approval for several expanded indications for the treatment of coronary artery disease (CAD) with the Prevail paclitaxel-coated percutaneous transluminal coronary angioplasty (PTCA) balloon catheter, or drug-coated balloon (DCB). The Prevail DCB now has the broadest range of CE Mark indications including bifurcation and is the only DCB indicated for treatment in patients with multivessel disease, acute coronary syn…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Drug Delivery Business broke the news in on Thursday, May 22, 2025.
Sources are mostly out of (0)

You have read 1 out of your 5 free daily articles.

Our use of cookies
Unlike other news sites, we do not share or sell your data to third-parties for targeted ads.
By continuing to use our application or website, you agree to our Terms of Service and Privacy Policy.